MINNEAPOLIS--(BUSINESS WIRE)--Ground breaking research on cancer stem cells as targets and normal stem cells in Immunotherapy will be discussed at the 2nd Annual Cancer Immunotherapy Conference in Washington DC on April 4-5, 2013.
As modern oncology, largely directed towards developing therapies that achieve tumor reduction, has been thus far unsuccessful in achieving long term management of cancer, much more needs to be done in identifying and appropriately leveraging targets associated with tumor initiation, relapse or metastasis. Immunotherapy holds the promise of achieving durable control of cancer if matched with appropriate targets borne by cancer cells responsible for relapse and metastasis.
At the 2nd Annual Cancer Immunotherapy Conference, significant findings on hematopoietic stem cells and T cell engineering for cancer immunotherapy, as well as cancer stem cells as a new category of targets for immune intervention in solid and hematological malignancies will be presented by nearly twenty experts in the fields of academia, pharmaceuticals and cancer research.
Speakers and panelists will be addressing and answer the following questions:
- What have been some of the most promising advances regarding definition of targets associated with cancer stem cells or tumor initiating cells in general?
- Why tumor initiating cells are potentially amenable to immune intervention? Have there been exciting advances in this area?
- How can targeting of cancer stem cells be more effectively achieved using a variety of immunotherapeutic platforms, such as antibodies, vaccines or immune effector cells?
Some of the speakers at this year’s conference include:
- Nicholas Restifo, MD, NIH, who will discuss strategies to utilize and engineer potent T stem cell-like memory cells against cancer antigens
- Raul Vizcardo, Ph.D., RIKEN Research Center for Allergy and Immunology, who will present late breaking results on re-programming pluripotent stem cells into anti-tumor T cells
- David Spencer, Ph.D., Bellicum Pharmaceuticals, who will discuss approaches to effectively harness genetically engineered immune effector cells for the therapy of cancer
- Philip Greenberg, MD, University of Washington, who will introduce a novel class of targets for T cell based immunotherapy, comprising oncogenic proteins expressed by leukemic stem cells
- John Yu, MD, Ph.D., Immunocellular Therapeutics, who will present the latest clinical results in utilizing active immunotherapy against cancer stem cells in solid tumors
This conference brings together leading scientists and C-Level executives from across the globe to present ground breaking research, case studies and new viewpoints. Please visit www.cancerimmunotherapyconference.com for the full list of speakers, agenda, and registration information.